<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03804372</url>
  </required_header>
  <id_info>
    <org_study_id>CLL1818</org_study_id>
    <nct_id>NCT03804372</nct_id>
  </id_info>
  <brief_title>The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide</brief_title>
  <acronym>CLL1818</acronym>
  <official_title>Prospective Study on the Incidence of Hepatitis B Virus Reactivation in Untreated Patients With Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we will evaluate the incidence of hepatitis B virus reactivation within the&#xD;
      first 6 months of treatment with rituximab, standard chemotherapy and TAF in patients with&#xD;
      diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, interventional, single arm, evaluating the incidence of&#xD;
      hepatitis B virus (HBV) reactivation within the first 6 months treatment period in HBsAg&#xD;
      positive patients treated for DLBCL/Chronic Lymphoid Leukemia with Rituximab, standard&#xD;
      chemotherapy, and TAF.&#xD;
&#xD;
      Approximate duration of the recruitment period based on the number of patients available The&#xD;
      duration of the recruitment period has been estimated at 12 months.&#xD;
&#xD;
      Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy&#xD;
      for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy&#xD;
      and withdrawn 12 months after the completion of chemotherapy. Then patients will be also&#xD;
      observed for further12 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients presenting hepatitis B virus reactivation</measure>
    <time_frame>Within 6 months following the start of treatment</time_frame>
    <description>Assessment of the percentage of patients presenting HBV reactivation within 6 months following the start of treatment with Rituximab, chemotherapy and TAF in in DLBCL and Chronic Lymphoid Leukemia patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients presenting hepatitis B virus reactivation</measure>
    <time_frame>After 12 months following the study entry and start of treatment</time_frame>
    <description>Assessment of the percentage of patients presenting HBV reactivation during and after the 12-month treatment of TAF as a single agent in in DLBCL and Chronic Lymphoid Leukemia patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients stratified by DLBCL and Chronic Lymphoid Leukemia with hepatitis related to the HBV infection or with liver failure during their participation in the study.</measure>
    <time_frame>After 31 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients in which chemotherapy is delayed due to HBV-reactivation.</measure>
    <time_frame>After 31 months from study entry</time_frame>
    <description>In terms of percentage of patients with a delay of at least 7 days between chemotherapy cycles stratified by DLBCL and chronic lymphoid leukemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with DLBCL and with Chronic Lymphoid Leukemia who survive</measure>
    <time_frame>After 31 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients experiencing adverse events.</measure>
    <time_frame>After 31 months from study entry</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Large-B-cell Diffuse Lymphoma</condition>
  <condition>Chronic Lymphoid Leukemia</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir alafenamide</intervention_name>
    <description>Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent according to ICH/EU/GCP and national local laws.&#xD;
&#xD;
          -  Male/non-pregnant/non-lactating female subjects &gt;18 years old with newly diagnosed&#xD;
             DLBCL/Chronic Lymphoid Leukemia who are going to receive treatment with rituximab in&#xD;
             combination with chemotherapy.&#xD;
&#xD;
          -  HBsAg positivity, serum HBV-DNA negative or positive (&lt;2000/IU), and normal liver&#xD;
             function, including alanine aminotransferase(ALT), aspartate aminotransferase(AST) and&#xD;
             bilirubin. (inactive carriers).&#xD;
&#xD;
          -  No previous treatment with antiviral drugs for HBV infection.&#xD;
&#xD;
          -  Patients with satisfactory renal function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hepatic insufficiency for any reason&#xD;
&#xD;
          -  History of other liver diseases such as hepatitis C, D, autoimmune hepatitis, primary&#xD;
             biliary cirrhosis, Wilsons' disease&#xD;
&#xD;
          -  Positive viral markers, such as IgM antibody to hepatitis A virus, hepatitis C virus,&#xD;
             IgG antibody to hepatitis D virus, IgM antibody to hepatitis E virus, or antibody to&#xD;
             HIV&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Other major systemic diseases, such as active infection, significant cardiac disease,&#xD;
             neurological deficit or psychiatric disorder, that the investigators consider being a&#xD;
             significant risk&#xD;
&#xD;
          -  Patients with moderate or severe renal failure.&#xD;
&#xD;
          -  Intolerance to any of the components of the therapeutic regimen. Treatment with any&#xD;
             investigational medicinal product (unapproved) in the last 30 days.&#xD;
&#xD;
          -  Any other disorder that, in the investigator's opinion, makes the patient ineligible&#xD;
             for recruitment or that could interfere in his/her participation or in the conclusion&#xD;
             of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Gentile</last_name>
    <role>Study Chair</role>
    <affiliation>Universit√† Sapienza di Roma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandra Micozzi</last_name>
    <role>Study Director</role>
    <affiliation>Universit√† Sapienza di Roma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <phone>+39 0670390514</phone>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <phone>+39 0670390514</phone>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universit√† degli Studi &quot;Sapienza&quot; - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <state>(rm)</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Gentile</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Gentile</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandra Micozzi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aon Ss. Antonio E Biagio E C. Arrigo - Alessandria - Soc Ematologia</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Pietrasanta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Area Vasta N. 5 Ascoli Piceno - S. Benedetto Del Tronto, Presidio Ospedaliero Av5 Osp. Gen. Prov.Le &quot;C.G.Mazzoni&quot; - Uoc Ematologia</name>
      <address>
        <city>Ascoli Piceno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piero Galieni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asl Lecce, Ospedale 'V. Fazzi' - Uo Ematologia</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ao Ospedali Riuniti &quot;Papardo Piemonte&quot; - Po Papardo - Messina - Sc Ematologia</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donato Mannina</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou Federico Ii - Napoli - Uoc Ematologia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio Pane</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou Maggiore Della Carita' Di Novara - Scdu Ematologia</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Gaidano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ao Ospedali Riuniti Villa Sofia Cervello - Palermo - Uo Ematologia Con Utmo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Patti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asl Pescara, Presidio Ospedaliero 'Spirito Santo' - Uoc Ematologia Clinica</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsa Pennese</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ausl Della Romagna, Ospedale &quot;Infermi&quot; - Rimini - Uo Ematologia</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Merli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou Integrata Di Verona, Policlinico G.B. Rossi - Uoc Ematologia</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Visco</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 8, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2019</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diffuse Large B-Cell Lymphoma</keyword>
  <keyword>chronic Lymphoid Leukemia HBsAg-positive</keyword>
  <keyword>Rituximab</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>alafenamide</keyword>
  <keyword>hepatitis B virus reactivation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

